Severity of cardiovascular disease outcomes among patients with hiv is related to markers of inflammation and coagulation

Journal of the American Heart Association

Volumn 3, Issue 3, 2014, Pages

  Nordell, Anna D ^a   McKenna, Matthew ^a   Borges, Alvaro H ^b   Duprez, Daniel ^c   Neuhaus, Jacqueline ^a   Neaton, James D ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cardiovascular disease; Inflammation

Indexed keywords

ALDESLEUKIN; ANTIRETROVIRUS AGENT; C REACTIVE PROTEIN; D DIMER; INTERLEUKIN 6; RECOMBINANT INTERLEUKIN 2; BIOLOGICAL MARKER; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D;

ADULT; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FATALITY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); BLOOD; COMPLICATION; MIDDLE AGED; ODDS RATIO;

ADULT; BIOMARKERS; BLOOD COAGULATION; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HIV INFECTIONS; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; ODDS RATIO;

EID: 84920875622     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.114.000844     Document Type: Article

References (36)

1. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol. 1996;144:537-547.
2. Engström G, Hedblad B, Stavenow L, Tydén P, Lind P, Janzon L, Lindgärde F. Fatality of future coronary events is related to inflammation-sensitive plasma proteins a population-based prospective cohort study. Circulation. 2004;110:27-31.
3. Sattar N, Murrary HM, Welsh P, Blauw GJ, Buckley BM, Cobbe S, de Craen AJM, Lowe GD, Jukema JW, Macfarlane PW, Murphy MB, Stott DJ, Westendorp RGJ, Shepherd J, Ford I, Packard CJ; for the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Study Group. Are markers of inflammation more strongly associated with risk for fatal than for non-fatal vascular events?. PLoS Med. 2009;6:e1000099.
4. van Wijk DF, Boekholdt SM, Wareham NJ, Ahmadi-Abhari S, Kastelein JJ, Stroes ES, Khaw KT. C-reactive protein, fatal and nonfatal coronary artery disease, stroke, and peripheral artery disease in the prospective EPIC-Norfolk cohort study. Arterioscler Thromb Vasc Biol. 2013;33:2888-2894.
5. Neuhaus J, Jacobs DR, Baker JV, Calmy A, Duprez D, La Rosa A, Kuller LH, Pett SL, Ristola M, Ross MJ, Shlipak MG, Tracy R, Neaton JD. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201:1788-1795.
6. Catalfamo M, Le Saout C, Lane HC. The role of cytokines in the pathogenesis and treatment of HIV infection. Cytokine Growth Factor Rev. 2012;23:207-214.
7. Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic hiv infection. Immunity. 2013;39:633-645.
8. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92:2506-2512.
9. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, Boccara F, Bingham A, Costagliola D. Increased risk of myocardial infarction in HIVinfected patients in France, relative to the general population. AIDS. 2010;24:1228-1230.
10. Obel N, Thomsen HF, Kronborg G, Larsen CS, Hildebrandt PR, Sørensen HT, Gerstoft J. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis. 2007;44:1625-1631.
11. Currier JS, Taylor A, Boyd F, Dezii CM, Kawabata H, Burtcel B, Maa JF, Hodder S. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr. 1999;33:506-512.
12. Freiberg MS, Chang CCH, Kuller LH, Skanderson M, Lowy E, Kraemer KL, Butt AA, Goetz MB, Leaf D, Oursler KA, Rimland D, Barradas MR, Brown S, Gilbert C, McGinnis K, Crothers K, Sico J, Crane H, Warner A, Gottlieb S, Gottdiener J, Tracy RP, Budoff M, Watson C, Armah KA, Doebler D, Bryant K, Justice AC. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013; 1-9.
13. Duprez DA, Neuhaus J, Kuller LH, Tracy R, Belloso W, De WITS, Drummond F, Lane HC, Ledergerber B, Lundgren J, Nixon D, Paton NI, Prineas RJ, Neaton JD; for the INSIGHT SMART Study Group. Inflammation, coagulation and cardiovascular disease in HIV-infected patients. PLoS One. 2012; 7: e44454.
14. + count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296.
15. SMART Study Group. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy, a randomized trial. Ann Intern Med. 2008;149:289-299.
16. Emery S, Abrams DI, Cooper DA, Darbyshire JH, Lane HC, Lundgren JD, Neaton JD; the ESPRIT Study Group. The evaluation of subcutaneous proleukin (R) (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. Control Clin Trials. 2002;23:198-220.
17. The INSIGHT-ESPRIT Study Group and SILCAAT Scientific Committee. Interleukin-2 therapy in patients with HIV infection. N Engl J Med. 2009;361:1548-1559.
18. Lifson AR, INSIGHT Endpoint Review Committee Writing Group, Belloso WH, Davey RT, Duprez D, Gatell JM, Hoy JF, Krum EA, Nelson R, Pederson C, Perez G, Price RW, Prineas RJ, Rhame FS, Sampson JH, Worley J; for the INSIGHT Study Group. Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials. HIV Clinical Trials. 2010; 11.4: 205-219.
19. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. J Am Coll Cardiol. 2007;50:2173-2195.
20. Kowalska JD, Friis-Møller N, Kirk O, Bannister W, Mocroft A, Sabin C, Reiss P, Gill J, Lewden C, Phillips A, D'Arminio Monforte A, Law M, Sterne J, DeWit S, Lundgren JD; for the CoDe Working Group; the D: A: D Study Group. The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology. Epidemiology. 2011;22:516-523.
21. Grund B, Baker J, Deeks S, Wolfson J, Wentworth D, Cozzi-Lepri A, Cohen C, Phillips A, Lundgren J, Neaton J; for the INSIGHT SMART/ESPRIT/SILCAAT Study Groups. Combined effect of interleukin-6 and D-dimer on the risk of serious non-AIDS conditions: data from 3 prospective cohorts (Abstract 60). In: Program and abstracts of the 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA; March 2013.
22. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentsgl.pdf. Accessed May 15, 2014.
23. Baker JV, Brummel-Ziedins K, Neuhaus J, Duprez D, Cummins N, Dalmau D, DeHovitz J, Lehmann C, Sullivan A, Woolley I, Kuller L, Neaton JD, Tracy RP. HIV replication alters the composition of extrinsic pathway coagulation factors and increases thrombin generation. J Am Heart Assoc. 2013;2:e000264.
24. Dellinger RP. Cardiovascular management of septic shock. Crit Care Med. 2003;31:946-955.
25. Levi M, van der Poll T, Büller HR. Bidirectional relation between inflammation and coagulation. Circulation. 2004;109:2698-2704.
26. Lassila R, Peltonen S, Lepäntalo M, Saarinen O, Kauhanen P, Manninen V. Severity of peripheral atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin. Arterioscler Thromb Vasc Biol. 1993;13:1738-1742.
27. Lee AJ, Fowkes FG, Lowe GD, Rumley A. Fibrin D-dimer, haemostatic factors and peripheral arterial disease. Thromb Haemost. 1995;74:828-832.
28. Whiteley W, Jackson C, Lewis S, Lowe G, Rumley A, Sandercock P, Wardlaw J, Dennis M, Sudlow C. Inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin-6. PLoS Med. 2009;6:e1000145.
29. Zanni MV, Abbara S, Lo J, Wai B, Hark D, Marmarelis E, Grinspoon SK. Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men. AIDS. 2013;27:1263-1272.
30. Fitch KV, Srinivasa S, Abbara S, Burdo TH, Williams KC, Eneh P, Lo J, Grinspoon SK. Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women. J Infect Dis. 2013;208:1737-1746.
31. Holloway CJ, Ntusi N, Suttie J, Mahmod M, Wainwright E, Clutton G, Hancock G, Beak P, Tajar A, Piechnik SK, Schneider JE, Angus B, Clarke K, Dorrell L, Neubauer S. Comprehensive cardiac magnetic resonance imaging and spectroscopy reveal a high burden of myocardial disease in HIV patients. Circulation. 2013;128:814-822.
32. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med. 2000;343:1139-1147.
33. James SK, Armstrong P, Barnathan E, Califf R, Lindahl B, Siegbahn A, Simoons ML, Topol EJ, Venge P, Wallentin L. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndromea GUSTO-IV substudy. J Am Coll Cardiol. 2003; 41:916-924.
34. Zamani P, Schwartz GG, Olsson AG, Rifai N, Bao W, Libby P, Ganz P, Kinlay S. Inflammatory biomarkers, death, and recurrent nonfatal coronary events after an acute coronary syndrome in the MIRACL study. J Am Heart Assoc. 2013;2: e003103.
35. De Servi S, Mariani M, Mariani G, Mazzone A. C-reactive protein increase in unstable coronary disease cause or effect? J Am Coll Cardiol. 2005;46:1496-1502.
36. Tseng ZH, Secemsky EA, Dowdy D, Vittinghoff E, Moyers B, Wong JK, Havlir DV, Hsue PY. Sudden cardiac death in patients with human immunodeficiency virus infection. J Am Coll Cardiol. 2012;59:1891-1896.